Who Qualifies for GLP-1 Injections? BMI Thresholds, Medical Criteria, and the Gray Areas
Medically Reviewed by
Board Certified Endocrinologist
Published
Mar 4, 2026
Last Reviewed
Mar 14, 2026
Sources
5 peer-reviewed
Standard
YMYL / E-E-A-T
Who Qualifies for GLP-1 Medications? The Short Answer
You qualify for FDA-approved GLP-1 weight loss medications (Wegovy, Zepbound) if your BMI is 30 or higher, or if your BMI is 27 or higher with at least one weight-related health condition such as high blood pressure, type 2 diabetes, or sleep apnea. Insurance coverage and prior authorization requirements add additional criteria beyond these FDA thresholds.
The FDA-Approved Indications: What the Labels Actually Say
The two most commonly prescribed GLP-1-based therapies for weight management have specific FDA-approved indications. Semaglutide 2.4mg (Wegovy), approved June 2021, is indicated for adults with BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity. Tirzepatide 2.5–15mg (Zepbound), approved November 2023, has the same BMI thresholds. The weight-related comorbidities that qualify for the '27 with comorbidity' threshold include type 2 diabetes, hypertension (BP ≥130/80 or on medication), dyslipidemia, obstructive sleep apnea, cardiovascular disease, non-alcoholic fatty liver disease, polycystic ovary syndrome (PCOS), and obesity-related osteoarthritis. These conditions are broadly defined — many patients are surprised to discover they qualify based on a comorbidity they hadn't connected to weight.
The BMI Reference Chart for GLP-1 Eligibility
Understanding where you fall in the BMI classification determines your baseline eligibility pathway. BMI below 18.5 (underweight) and 18.5–24.9 (normal weight) are not eligible under FDA labeling. BMI 25.0–26.9 (overweight) is not eligible without a qualifying comorbidity. BMI 27.0–29.9 (overweight) is eligible with at least one comorbidity. BMI 30.0–34.9 (Obesity Class I), 35.0–39.9 (Class II), and 40+ (Class III) are all eligible with no comorbidity required. To calculate your BMI: divide your weight in kilograms by the square of your height in meters. In imperial units: [weight (lbs) ÷ height (inches)²] × 703. A 5'6" person reaches BMI 27 at approximately 167 lbs and BMI 30 at approximately 186 lbs.
Why BMI Is Flawed but Unavoidable
BMI is a deeply imperfect measure — it was developed in the 1830s as a population statistics tool, never designed as an individual health metric. BMI underestimates risk in people who carry fat viscerally (around organs), who may have more metabolic risk than someone with a higher but peripherally distributed BMI. BMI overestimates risk in muscular individuals where elevated BMI reflects muscle mass rather than fat. Ethnicity matters significantly: the WHO and American Diabetes Association recommend evaluation for GLP-1 therapy at BMI ≥23 in South Asian, East Asian, and some Latino populations, though FDA labels haven't been updated to reflect this. Waist circumference (>35 inches in women, >40 inches in men) is a better predictor of metabolic risk than BMI alone for many patients.
Insurance Eligibility in 2026: The Real-World Picture
FDA approval and insurance coverage are two different things. As of March 2026, Medicare covers Wegovy for patients with established cardiovascular disease (heart attack, stroke, or peripheral arterial disease) based on the SELECT trial's cardiovascular benefit data — a major change from prior policy. Medicaid coverage varies dramatically by state; approximately 18 states now have Medicaid coverage for at least one GLP-1 weight loss agent. Most major commercial insurers cover Wegovy and/or Zepbound with prior authorization, typically requiring documented BMI, a qualifying comorbidity if BMI is 27–29.9, and evidence of previous weight management attempts (diet, exercise, or behavioral program) for 3–6 months. The documentation your provider submits matters enormously — thorough clinical notes about comorbidities and failed prior treatments significantly improve approval rates.
Absolute Contraindications to GLP-1 Therapy
Regardless of BMI, these conditions preclude GLP-1 use: personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia type 2 (MEN2) syndrome, history of severe acute pancreatitis, pregnancy, and known hypersensitivity to the drug or its excipients. Relative contraindications requiring individualized risk-benefit discussion include diabetic gastroparesis (gastric emptying already slowed), history of cholelithiasis (GLP-1 agents modestly increase gallstone risk), severe renal impairment (monitor for dehydration), and severe hepatic impairment (limited data). If you have any of these conditions, discuss them openly with your prescribing physician before starting.
Off-Label Use at Lower BMI: What You Should Know
A growing number of providers prescribe GLP-1 agents off-label for patients with BMI 24–26, particularly when significant visceral adiposity is demonstrated, metabolic syndrome criteria are met, prediabetes is documented, or there is a strong family history of type 2 diabetes. Off-label prescribing is legal and sometimes clinically appropriate. However, insurance will almost never cover these prescriptions, and the benefit-to-risk ratio at lower BMIs is less clearly established from clinical trials. If your BMI is in this range, expect to pay out-of-pocket or through manufacturer assistance programs.
How to Prepare for the Eligibility Conversation With Your Doctor
Come to the appointment with your BMI pre-calculated (know your weight and height), a list of all diagnosed comorbidities with dates of diagnosis or current treatment, your weight history and previous management attempts, and your current medications. If your BMI is in the 27–29.9 range, focus the conversation specifically on comorbidities. Hypertension managed with medication fully qualifies. Prediabetes may qualify depending on your insurer's definition. If your doctor is unfamiliar with current eligibility criteria or quickly dismisses the question, seeking a second opinion from an obesity medicine specialist or endocrinologist is entirely reasonable.
Frequently Asked Questions
These answers are for informational purposes only. Always consult your physician for personalized medical advice.
Was this article helpful?
Scientific References & Further Reading
- Wilding JPH et al. — Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021.
- Jastreboff AM et al. — Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022.
- FDA Drug Approvals Database — GLP-1 Receptor Agonists. U.S. Food & Drug Administration.
- PubMed — GLP-1 Receptor Agonist Research Index. National Library of Medicine.
- Mayo Clinic — Semaglutide (GLP-1 Agonist): Uses, Side Effects, and Dosing. Mayo Clinic Drug Reference.
This content is produced in accordance with GLP-1 Health's editorial standards and is based on peer-reviewed clinical evidence from the sources cited above. It does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.
Continue Your GLP-1 Research
GLP-1 Medications: Complete 2026 Comparison Guide (Wegovy, Ozempic, Zepbound, Mounjaro)
Drug Comparison · 15 min read
Semaglutide Weight Loss Results After 6 Months: What the Data Actually Shows
Results & Data · 11 min read
Wegovy vs. Ozempic in 2026: Same Molecule, Very Different Drugs
Drug Comparison · 11 min read
